よむ、つかう、まなぶ。
08【参考資料３】International Coalition of Medicines Regulatory Authorities SARS-CoV-2 Variant Workshop（Thursday 30 June 2022） (1 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_26922.html |
| 出典情報 | 厚生科学審議会 予防接種・ワクチン分科会（第33回 7／22）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
1
【参考資料３】
2
International Coalition of Medicines Regulatory Authorities
3
SARS-CoV-2 Variant Workshop
4
Thursday 30 June 2022, 13:00 - 15:30 CET
5
Co-chairs: Dr Peter Marks (US FDA) and Dr Marco Cavaleri (EMA)
6
7
Welcome and objectives of workshop
8
Following-up on the January ICMRA Omicron variant workshop, the objectives
9
of this workshop were to discuss the emerging evidence and preliminary data
10
shared by vaccine developers on adapted vaccines addressing emerging variants,
11
with the aim of ensuring global alignment on the criteria for the selection of
12
adapted vaccines and regulatory requirements to address new waves of COVID-
13
19. Emer Cooke, Executive Director of the EMA opened the ICMRA SARS-CoV-
14
2 variant workshop.
15
16
Latest developments on virus evolution, adapted SARS-CoV-2 vaccines
17
and host responses induced.
18
Peter Marks (FDA) and Rogerio Gaspar (WHO), on behalf of The Technical
19
Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC),
20
presented the latest developments regarding SARS-CoV-2 virus evolution,
21
vaccine effectiveness against Omicron and cross-neutralization data against
22
Omicron, including Omicron descendent lineages.
23
24
Since the identification of Omicron as a Variant of Concern (VOC) in November
25
2021, Omicron has continued to evolve, leading to increased viral diversity, with
26
Omicron descendent lineages BA.4/BA.5 currently the dominant variant in many
27
locations. Mutations present in these Omicron descendent lineages may be
28
associated with higher infectivity and escape from existing immunity. Omicron is
29
displacing other variants in all six WHO regions. Antigenic cartography has shown
1
【参考資料３】
2
International Coalition of Medicines Regulatory Authorities
3
SARS-CoV-2 Variant Workshop
4
Thursday 30 June 2022, 13:00 - 15:30 CET
5
Co-chairs: Dr Peter Marks (US FDA) and Dr Marco Cavaleri (EMA)
6
7
Welcome and objectives of workshop
8
Following-up on the January ICMRA Omicron variant workshop, the objectives
9
of this workshop were to discuss the emerging evidence and preliminary data
10
shared by vaccine developers on adapted vaccines addressing emerging variants,
11
with the aim of ensuring global alignment on the criteria for the selection of
12
adapted vaccines and regulatory requirements to address new waves of COVID-
13
19. Emer Cooke, Executive Director of the EMA opened the ICMRA SARS-CoV-
14
2 variant workshop.
15
16
Latest developments on virus evolution, adapted SARS-CoV-2 vaccines
17
and host responses induced.
18
Peter Marks (FDA) and Rogerio Gaspar (WHO), on behalf of The Technical
19
Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC),
20
presented the latest developments regarding SARS-CoV-2 virus evolution,
21
vaccine effectiveness against Omicron and cross-neutralization data against
22
Omicron, including Omicron descendent lineages.
23
24
Since the identification of Omicron as a Variant of Concern (VOC) in November
25
2021, Omicron has continued to evolve, leading to increased viral diversity, with
26
Omicron descendent lineages BA.4/BA.5 currently the dominant variant in many
27
locations. Mutations present in these Omicron descendent lineages may be
28
associated with higher infectivity and escape from existing immunity. Omicron is
29
displacing other variants in all six WHO regions. Antigenic cartography has shown
1